Aminoisoquinolines: Design and synthesis of an orally active benzamidine isostere for the inhibition of factor Xa.

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 17, 1999, Pages 2539-2544

  Choi Sledeski, Y M ^a   Becker, M R ^a   Green, D M ^a   Davis, R ^a   Ewing, W R ^a   Mason, H J ^a   Ly, C ^a   Spada, A ^a   Liang, G ^a   Cheney, D ^a   Barton, J ^a   Chu, V ^a   Brown, K ^a   Colussi, D ^a   Bentley, R ^a   Leadley, R ^a   Dunwiddie, C ^a   Pauls, H W ^a  

^a Rhône Poulenc Rorer ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLIDONE DERIVATIVE; AMINOISOQUINOLINE DERIVATIVE; BENZAMIDINE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; SERINE PROTEINASE; SULFONAMIDOPYRROLIDINONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; CELL MEMBRANE PERMEABILITY; DOG; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; IN VIVO STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BINDING SITES; DOGS; FACTOR XA; ISOQUINOLINES; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033530140     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00421-7     Document Type: Article

References (31)

1. (a) Davie, E. W.; Fujikawa, K.; Kisiel, W. Biochemistry 1991, 30, 10363.
2. (b) Colman, R. W.; Marder, V. J.; Salzman, E. W.; Hirsh, J. In Hemostasis and Thrombosis Basic Principles and Clinical Practice; 3rd Ed. J.B. Lippincott: Philadelphia, 1994; pp 3-18.
3. (a) Kaiser, B. Clin. Appl. Thrombosis/Hemostasis 1997, 3, 16.
4. (b) Kaiser, B. Drugs of The Future 1998, 23, 423.
5. For reviews see: (a) Ewing, W. R.; Pauls, H. W.; Spada, A. P. Drugs of The Future, in press.
6. (b) Kaiser, B.; Hauptmann, J. Cardiovasc. Drug Rev. 1994, 12, 225.
7. (c) Al-Obeidi, F.; Ostrem, J. A. Drug Disc. Today 1998, 3, 223.
8. (a) Tidwell, R. R; Webster, W. P.; Shaver, S. R. ; Geratz, J. D. Thromb. Res. 1980, 19: 339.
9. (b) Stürzebecher, J.; Stürzebecher, U.; Vieweg, H.; Wagner, G.; Hauptmann, J.; Martwardt, F. Thromb. Res. 1989, 54, 245.
10. (a) Galemmo, R. A.; Maduskuie, T. P.; Dominguez, C.; Rossi, K. A.; Knabb, R. M.; Wexler, R. R.; Stouten, P. F. W. Biorg. Med. Chem. Lett. 1998, 8, 2705.
11. (b) Shaw, K. J.; Guilford, W. J.; Dallas, J. L.; Koovakkaat, S. K.; McCarrick, M. A.; Liang, A.; Light, D. R.; Morrissey, M. J. Med. Chem. 1998, 41, 3551.
12. Ewing, W. R.; Choi-Sledeski, Y. M.; Becker, M.; Manetta, V.; Green, D.; Davis, R.; Mason, H.; Ly, C.; Cha, D.; McGarry, D.; Dankulich, W. P.; Spada, A.; Cheney, D.; Mason, J.; Brown, K.; Colussi, D.; Chu, V.; Bentley, R.; Morgan, S.; Heran, C.; Leadley, R.; Dunwiddie, C.; Perrone, M.; Pauls, H. W. Presented at the 215th Natl. Meeting of The American Chemical Society, Dallas, TX, March 1998; MED1203.
13. Marquart, M.; Walter, J.; Diesenhofer, J.; Bode, W.; Huber, R. Crystallogr., Sect.B: Struct. Sci. 1983, B39, 480.
14. Sturzebecher, J.; Vieweg, H.; Wikstrom, P.; Turk, D.; Bode, W. BiolChem. Hoppe-Seyler 1992, 373, 491.
15. (a) von Bielenberg, G.W.; Kriegelstein, J. Arzneim.-Forsch./Drug Rs. 1984, 34, 958-67.
16. (b) Hauptmann, J. Folia Haematol. (Lpz) 1982, 109, 89.
17. Sanderson, P. E. J.; Naylor-Olsen, A.M. Curr.Med. Chem. 1998, 5, 289.
18. (a) Dyke, S. F.; Kinsman, R. G. In The Chemistry of Heterocyclic Compounds; Weissberger, A.; Taylor, E.C., Eds.; John Wiley & Sons: New York, 1981; Vol. 38 (1), p 8.
19. (b) Elderfield, R. C. In Heterocyclic Compounds; Elderfield, R. C., Ed.; John Wiley & Sons: New York, 1960, Vol. 4, p 169.
20. Jones, G.B.; Moody, C.J. J. Chem. Soc. Perkin Trans 1989, 12, 2455.
21. Nuvole, A.; Pinna G. A. J. Heterocyclic Chem. 1978, 15, 1513.
22. Eloy, F; Deryckere, A. Helv. Chim. Acta 1970, 3, 645.
23. Klemm, L.H.; Louris, J. N. J. Heterocyclic Chem. 1984, 21, 785.
24. 1HNMR and MS spectra: Choi-Sledeski, Y. M.; Pauls, H. W.; Barton, J. N.; Ewing, W. R.; Green, D. M.; Becker, M. R. WO9825611, 1998; Chem. Abstr. 1998, 129, 81744.
25. In vitro assays were run in triplicate as per: Bostwick, J. S.; Bentley, R.; Morgan, S.; Brown, K.; Chu, V.; Ewing, W.R.; Spada, A.; Pauls, H.; Perrone, M.; Dunwiddie, C.T.; Leadley, R.J.; Thromb. Haemost. 1999, 81, 157.
26. Walter, E.; Kissel, T.; Reers, M.; Dickneite, G; Hoffmann, D.; Stuber, W. Parm. Res. 1995, 12, 360.
27. Choi-Sledeski, Y. M.; Pauls, H. W.; Becker, M. R.; Ewing, W. R.; Green, D.; Ly, C.; Davis, R.; Morton, G.; Mason, H. J.; Gong, Y.; Gardner, C.; Jiang, J. Z.; Li, A.; Spada, A.; Barton, J.; Liang, G.; Chu, V.; Brown, K.; Colussi, D.; Bentley, R.; Leadley, R.; Dunwiddie, C.; Maignan, S.; Guilloteau, J. P. Abstracts of Papers, 217th Natl. Meeting of The American Chemical Society, Anaheim, CA, American Chemical Society: Washington DC, 1998; MED180.
28. Rebello, S. S.; Miller, B. V.; Basler, G. C.; Lucchesi, B. R. J. Cardiovasc. Pharmacol. 1997, 29, 240.
29. Hara, T.; Yokoyama, A.; Ishihara, H.; Yokoyama, Y.; Nagahara, T.; Iwamoto, M. Thromb. Haemost. 1994, 71, 314.
30. The binding model was constructed with Chem-X/DiR and InsightII/Discover Software using fXa coordinates (1HCG) available in the Brookhaven Data Base: Tulinsky, A.; Padmanbhan, K.; Padmanbhan, K. P.; Park, C.H.; Bode, W.; Huber, R.; Blankenship, D. T.; Cardin, A. D.; Kiesel, W. J. Mol. Biol. 1993, 232, 947.
31. Aminoisoquinoline containing thrombin inhibitors were recently reported: Rewinkel, J.; Lucas, H.; van Galen, P.; Noach, A.; van Dinther, T.; Rood, A.; Jenneboer, A.; van Boeckel, C. Bioorg, Med. Chem. Lett. 1999, 9, 685.